Immunotherapy combo shows promise in hodgkin lymphoma trial
NCT ID NCT07234487
First seen Nov 18, 2025 · Last updated Jun 04, 2026 · Updated 20 times
Summary
This study compares two first-line treatments for advanced Hodgkin lymphoma. One group gets a new combination of the immunotherapy drug nivolumab plus chemotherapy (AVD), while the other group receives standard chemotherapy (BEACOPP-like). The goal is to see which approach is safer and more effective. About 178 adults aged 18-60 with newly diagnosed stage IIB, III, or IV Hodgkin lymphoma will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.N.Bakulev Center for cardiovascular surgery of the Russian Ministry of Health
RECRUITINGMoscow, Russia
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
National Medical and Surgical Center named after N.I. Pirogov
RECRUITINGMoscow, Russia
Contact Email: •••••@•••••
-
St. Petersburg State Pavlov Medical University
RECRUITINGSaint Petersburg, Russia
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.